Two other studies did not report a significant difference between the immunotherapy agents and the risk for the development of ICI-DM, but did mention that the onset of ICI-DM was earlier in those receiving combination treatment than in those receiving single-agent PD-1/PD-L1 [32,35]. This evidence concerns the gene PDCD1 and diabetes mellitus.